Journal for ImmunoTherapy of Cancer – Page 70

Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8+ T cells

15 de July de 2025 by

Background
Tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) facilitates tumor progression, but the role of immune cell-intrinsic PCSK9 in tumor control remains unclear.

Methods
Orthotopic models of pancreatic cancer and melanoma in…

Unveiling the mechanisms of CEBPD-orchestrated TAM polarization through RGS2/PAR2 pathway and its impact on ICB efficacy in clear cell renal cell carcinoma

14 de July de 2025 by

Background
The polarization status and function of tumor-associated macrophages (TAMs) influence tumor progression and patients’ prognosis. CCAAT/enhancer-binding proteins (CEBPs) family are important transcriptional factors in macrophages diffe…

JAK-STAT-activated, fratricide-resistant CAR-T cells targeting membrane-bound TNF effectively treat AML and solid tumors

14 de July de 2025 by

Background
While chimeric antigen receptor (CAR)-T cell therapy exhibits a robust therapeutic efficacy against B-cell malignancies and multiple myeloma, its efficacy and safety have not been established for acute myeloid leukemia (AML) and solid tumor…

T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles

14 de July de 2025 by

Background
Ex vivo chimeric antigen receptor (CAR)-T therapies have revolutionized cancer treatment. However, treatment accessibility is hindered by high costs, long manufacturing times, and the need for specialized centers and inpatient care. Strateg…

Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915

11 de July de 2025 by

Purpose
CheckMate 915 (NCT03068455) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that correlate with ben…

Shared epitopes create safety and efficacy concerns in several cancer vaccines

11 de July de 2025 by Kellermann, G., Mograbi, B., Hofman, P., Brest, P.

Tumor-associated antigens (TAAs) are the targets of several therapeutic cancer vaccines. However, many TAAs contain epitopes identical to unintended targets, creating shared epitopes with other human proteins in normal tissues. Moreover, for some TAAs…

Commentary on differential impact of TIM-3 ligands on NK cell function

11 de July de 2025 by van de Ven, R.

T-cell immunoglobin and mucin-domain containing molecule 3 (TIM-3) is an immune checkpoint receptor and a target for immune checkpoint blockers (ICBs). Unfortunately in human patients the success rate of anti-TIM-3 ICB remains rather limited. Multiple…

Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity

11 de July de 2025 by Ono, R., Tokuoka, S., Tachibana, M., Ishii, K. J., Sakurai, F., Mizuguchi, H.

Background
Oncolytic adenoviruses (OAds) mediate superior antitumor effects both by inducing direct oncolysis and activating antitumor immunity. Previously, we developed a novel OAd fully composed of human adenovirus serotype 35 (OAd35). OAd35 efficie…

Correction: Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers

10 de July de 2025 by Journal for ImmunoTherapy of Cancer current issue

Malevolent alliance of MYBL2hi cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer

10 de July de 2025 by Chen, H., Jin, Z., Peng, Y., Li, Y., Li, Z., Zhang, X., Xie, Y., Dong, J., Ma, L., Ji, Z.

Background
Neoadjuvant immune checkpoint blockade (nICB) has revolutionized cancer treatment, yet the underlying mechanisms of resistance in bladder cancer remain to be explored.

Methods
We conducted single-cell RNA sequencing (scRNA-seq) on peripher…